Development of Broadly Protective Filovirus Vaccines


Programme Category

EU Competitive Programmes

Programme Name

Funding under projects

Programme Description

Funding provided under previews programmes.

Programme Details

Identifier Code



Development of Broadly Protective Filovirus Vaccines


CfP-FILOVAX aims to support the development of broadly protective Filovirus vaccines with a focus on preventive use, with co-funding from the European Union.

Detailed Call Description

It will be achieved through two focused areas of work:

  1. the development of multivalent vaccines comprising several antigens covering filoviruses known to be responsible for human disease outbreaks;
  2. the development of a more systematic approach for the state-of-the-art immunogen design and testing of virus-specific or more broadly reactive immunogens for members of the Filovirus family (contributing to a “vaccine library”).

The output of the work under CfP-FILOVAX will be (1) multivalent vaccines with phase II clinical data to support a pathway to licensure, or (2) exemplar vaccine candidates based on immunogen designs from the Filovirus family vaccine library with phase I clinical data.

CEPI invites applicants (i.e. relevant vaccine development organisations and/or consortia) to submit proposals for funding. Applicants should submit detailed plans for product development, manufacturing, and related activities, including a clear development plan that describes milestones, timelines, criteria for success, and an assessment of risks and proposed mitigation measures to ensure their resolution. Emphasis on plans to achieve equitable access to the vaccine(s) by providing affordable and timely vaccine availability in low-resource settings consistent with CEPI’s mission is a requirement for this CfP.

Call Total Budget

€50.000.000 and is expected to fund 3 to 5 awards.

Financing percentage by EU or other bodies / Level of Subsidy or Loan

Please note, those applicants who can provide co-funding, complementary funding, or in-kind support to extend the impact of CEPI’s funding will be considered favourably. Funding must reflect the proposed activities and agreed conditions of the award decision made by CEPI. CEPI reserves the right to terminate agreements according to mutually agreed “go/no-go” decision criteria.

CfP-FILOVAX projects must be completed within 3-4 years from signature and should have achieved significant progress by 12 to 15 months after the signing of a CEPI funding agreement.

Thematic Categories

  • Health
  • Research, Technological Development and Innovation

Eligibility for Participation

  • Businesses
  • Educational Institutions
  • International Organisations
  • Large Enterprises
  • Legal Entities
  • Other Beneficiaries
  • Private Bodies
  • Researchers/Research Centers/Institutions
  • State-owned Enterprises

Eligibility For Participation Notes

Τhis Call is open worldwide to all types of non-profit research organisations, for-profit companies, international organisations and foundations, joint R&D ventures, government research organisations, and academic institutions. Applicants must be legal entities, or consortia comprised of legal entities. Applicants must own the technology proposed or have the rights to develop and commercialise the vaccine incorporating the proposed technology.

Applicants must meet the following criteria (for the Development of multivalent Filovirus vaccines):

  • Existing monovalent or multivalent vaccines should have preclinical PoC, identified production process and analytical methods, and ideally phase I clinical safety and immunogenicity data.
  • Proposed multivalent vaccines should cover at least two Filoviruses.
  • At least one of the partners in the applicant organisations or consortia of partnering organisations should have experience in human vaccine development, clinical development, and manufacturing

Applicants must meet the following criteria (for the Creation and evaluation of a vaccine library for a range of Filoviruses):

  • Demonstrated capability for immunogen design using state-of-the-art methodologies.
  • Ability to express and characterise in vitro vaccine candidates/designs.
  • Ability to perform animal studies and relevant assays to confirm vaccine immunogenicity, and efficacy if animal models are available.

Applicants based in the Global South and/or partnerships that include developers in the Global South are encouraged to apply.
Applications by consortia of partners with complementary competences are encouraged.

Call Opening Date


Call Closing Date


EU Contact Point